Symbol | Exchange | Currency |
|---|
ADMA Biologics (NASDAQ:ADMA) has entered into a senior secured term loan facility with Perceptive Advisors for up to $72.5M under two funding tranches.The first tranche of $45M was...
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Oil & Gas, Telecoms and Consumer Services sectors led shares lower. At the close in NYSE, the...
ADMA Biologics (NASDAQ:ADMA) has filed a prospectus for a $100M mixed shelf offering and the sale of ~4.3M shares of common stock by a current investor.Now read: Syndax...
Investors in ADMA Biologics (NASDAQ:ADMA), Inc. ADMA need to pay close attention to the stock based on moves in the options market lately. That is because the May 20, 2022 $2.50...
1. ADMA Biologics (ADMA)ADMA Biologics (NASDAQ:ADMA) in the biotech group, has had three strong days in a row, exploding from 1.50 to 3.50 before backing off, Monday alone gaining...
CASI Pharmaceuticals (NASDAQ:CASI) had a nice-looking mini coil or flag on Tuesday, up 25 cents, or 3 1/2%, to 7.30, on 177,134 shares. If we break out across the double top, which...
ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Sell | Buy | Sell |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Sell | Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 91.82 | 91.92 | 86.82 | +9.51 | +11.55% | 12.56M | NYSE | |||
| 95.51 | 95.85 | 90.74 | +2.86 | +3.09% | 23.65M | NASDAQ | |||
| 45.14 | 45.60 | 43.71 | +2.25 | +5.25% | 380.94K | NYSE | |||
| 1.304 | 1.49 | 1.22 | +0.144 | +12.40% | 535.31K | NASDAQ | |||
| 0.9305 | 0.9597 | 0.9099 | -0.0895 | -8.77% | 5.56K | NASDAQ | |||
| 310.34 | 312.99 | 303.95 | +4.86 | +1.59% | 122.83K | NYSE | |||
| 0.58 | 0.85 | 0.55 | -0.80 | -57.86% | 3.63M | NASDAQ | |||
| 0.1851 | 0.193 | 0.185 | +0.0002 | +0.11% | 1.11M | NASDAQ | |||
| 18.87 | 19.47 | 17.88 | +2.19 | +13.11% | 301.25K | NYSE | |||
| 81.25 | 82.14 | 78.74 | +3.11 | +3.98% | 1.28M | NYSE | |||
| 184.11 | 185.63 | 183.80 | +0.68 | +0.37% | 38.82K | NASDAQ | |||
| 134.13 | 136.70 | 114.70 | +18.96 | +16.46% | 4.11M | NYSE | |||
| 0.734 | 0.74 | 0.71 | -0.005 | -0.65% | 160.67K | NYSE | |||
| 21.44 | 21.64 | 20.30 | +0.92 | +4.48% | 1.86M | NYSE | |||
| 24.76 | 25.44 | 24.76 | -0.06 | -0.23% | 41.72K | NYSE |